NeoGenomics, Inc. (NG9)
FSX
Closed
Oct 9, 2026
Day's Range
14.1052 wk Range
6.20Overview - NG9 - NeoGenomics, Inc.
Key Statistics
Valuation
Enterprise Value
2.05B
P/E (Trailing)
‪-19.38‬
P/E (Forward)
‪-97.81‬
PEG Ratio
‪0.18‬
Price / Sales (TTM)
‪2.62‬
Price / Book
‪2.95‬
EV / EBITDA
‪95.10‬
Profitability
Gross Margin
‪45.56%‬
Profit Margin
‪-6.77%‬
Operating Margin
‪-4.84%‬
Return on Assets
‪-1.88%‬
Return on Equity
‪-6.32%‬
Ownership
Shares Outstanding
127.91M
Float
117.01M
Held by Insiders
‪2.10%‬
Held by Institutions
‪115.17%‬
Price stats
Beta
‪1.74‬
50-Day Avg
‪14.76‬
200-Day Avg
‪10.49‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - NG9 - NeoGenomics, Inc.
Peers - NG9 - NeoGenomics, Inc.
Peer Comparison
Compared with companies in Diagnostics & Research listed on FSX.
Profile Summary - NG9 - NeoGenomics, Inc.
About
NeoGenomics Inc. is a leading cancer diagnostics company specializing in oncology genetics testing and information services. It offers one of the most comprehensive menus of oncology-focused tests worldwide, including next-generation sequencing (NGS), comprehensive genomic profiling, and advanced assays like RaDaR ST…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
